{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:24:16Z","timestamp":1790267056934,"version":"4.1.0"},"reference-count":20,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cephalalgia"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Published evidence supporting efficacy of calcitonin gene-related peptide receptor antagonists as acute migraine treatments in males is limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To fill the gap, we present male and female data from four ubrogepant and four atogepant randomized, double-blind, placebo-controlled trials for acute and preventive treatment of migraine, respectively. Acute outcomes included 2-h pain freedom and absence of most bothersome symptom (co-primary; headache-phase randomized, double-blind, placebo-controlled trials); absence of moderate-to-severe headache within 24\u2005h (primary; prodrome randomized, double-blind, placebo-controlled trial). Preventive outcome included change from baseline in mean monthly migraine days across 12 weeks (primary).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Pooled data from phase 3 headache-phase ubrogepant randomized, double-blind, placebo-controlled trials showed similar rates of pain freedom (19.4% vs 21.1%) and absence of most bothersome symptom (35.1% vs 39.0%) 2\u2005h post-dose between males and females, respectively. Time course of pain freedom and absence of most bothersome symptom over 48\u2005h was similar between male and female subgroups. Comparable reductions in mean monthly migraine days across 12-week treatment periods were found between males and females treated with atogepant 60 mg once-daily in pooled episodic migraine and chronic migraine randomized, double-blind, placebo-controlled trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion\/Interpretation<\/jats:title>\n                    <jats:p>In ubrogepant and atogepant randomized, double-blind, placebo-controlled trials, although analysis power for males is limited due to small sample sizes, evidence supports similar treatment effects in males and females with migraine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov: NCT02828020; NCT02867709; NCT04492020; NCT01613248; NCT02848326; NCT03777059; NCT04740827; NCT03855137<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03331024251320610","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:55:42Z","timestamp":1740128142000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy of ubrogepant and atogepant in males and females with migraine: A secondary analysis of randomized clinical trials"],"prefix":"10.1177","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3260-5904","authenticated-orcid":false,"given":"Peter J.","family":"Goadsby","sequence":"first","affiliation":[{"name":"NIHR-King's Clinical Research Facility, King's College, London, UK"},{"name":"Department of Neurology, University of California, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4394-7136","authenticated-orcid":false,"given":"Tim P.","family":"J\u00fcrgens","sequence":"additional","affiliation":[{"name":"Headache Centre North-East, Department of Neurology, University Medical Center Rostock, Rostock, Germany"},{"name":"Department of Neurology, KMG Hospital G\u00fcstrow, G\u00fcstrow, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8199-0020","authenticated-orcid":false,"given":"Elimor","family":"Brand-Schieber","sequence":"additional","affiliation":[{"name":"AbbVie, North Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8698-941X","authenticated-orcid":false,"given":"Krisztian","family":"Nagy","sequence":"additional","affiliation":[{"name":"AbbVie, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5243-0793","authenticated-orcid":false,"given":"Yingyi","family":"Liu","sequence":"additional","affiliation":[{"name":"AbbVie, North Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8267-9210","authenticated-orcid":false,"given":"Ramesh","family":"Boinpally","sequence":"additional","affiliation":[{"name":"AbbVie, North Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7986-4447","authenticated-orcid":false,"given":"Sven","family":"Stodtmann","sequence":"additional","affiliation":[{"name":"AbbVie, Ludwigshafen am Rhein, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2376-8878","authenticated-orcid":false,"given":"Joel M.","family":"Trugman","sequence":"additional","affiliation":[{"name":"AbbVie, North Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01402-2"},{"key":"e_1_3_5_3_2","doi-asserted-by":"crossref","unstructured":"GBD 2016 Neurology Collaborators. Global regional and national burden of neurological disorders 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2019; 18: 459\u2013480.","DOI":"10.1016\/S1474-4422(18)30499-X"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410381145"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15778"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(16)30293-9"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0286453"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813049"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.16711"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102416653233"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01683-5"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30234-9"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035908"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01049-8"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00025-5"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1159\/000521697"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231159366"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2023.2335"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/03331024241238153"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0364-19.2019"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1137-21.2022"}],"container-title":["Cephalalgia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024251320610","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03331024251320610","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024251320610","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:46:46Z","timestamp":1777387606000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03331024251320610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1177\/03331024251320610"],"URL":"https:\/\/doi.org\/10.1177\/03331024251320610","relation":{},"ISSN":["0333-1024","1468-2982"],"issn-type":[{"value":"0333-1024","type":"print"},{"value":"1468-2982","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]},"article-number":"03331024251320610"}}